Literature DB >> 28529312

Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.

L Hinze1, A Möricke2, M Zimmermann1, S Junk1, G Cario2, E Dagdan1, C P Kratz1, V Conter3, M Schrappe2, M Stanulla1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28529312     DOI： 10.1038/leu.2017.154

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.

Authors:  Valentino Conter; Maria Grazia Valsecchi; Daniela Silvestri; Myriam Campbell; Eduardo Dibar; Edina Magyarosy; Helmut Gadner; Jan Stary; Yves Benoit; Martin Zimmermann; Alfred Reiter; Hansjörg Riehm; Giuseppe Masera; Martin Schrappe
Journal:  Lancet       Date:  2007-01-13       Impact factor: 79.321

2.  IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

Authors:  Petra Dörge; Barbara Meissner; Martin Zimmermann; Anja Möricke; André Schrauder; Jean-Pierre Bouquin; Denis Schewe; Jochen Harbott; Andrea Teigler-Schlegel; Richard Ratei; Wolf-Dieter Ludwig; Rolf Koehler; Claus R Bartram; Martin Schrappe; Martin Stanulla; Gunnar Cario
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

3.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.

Authors:  Valentino Conter; Claus R Bartram; Maria Grazia Valsecchi; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Maurizio Aricò; Martin Zimmermann; Georg Mann; Giulio De Rossi; Martin Stanulla; Franco Locatelli; Giuseppe Basso; Felix Niggli; Elena Barisone; Günter Henze; Wolf-Dieter Ludwig; Oskar A Haas; Giovanni Cazzaniga; Rolf Koehler; Daniela Silvestri; Jutta Bradtke; Rosanna Parasole; Rita Beier; Jacques J M van Dongen; Andrea Biondi; Martin Schrappe
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

4.  Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.

Authors:  Aurélie Caye; Kheïra Beldjord; Kelly Mass-Malo; Séverine Drunat; Jean Soulier; Virginie Gandemer; André Baruchel; Yves Bertrand; Hélène Cavé; Emmanuelle Clappier
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Authors:  Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

Review 6.  Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.

Authors:  Lynda M Vrooman; Lewis B Silverman
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

7.  IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Authors:  E Clappier; N Grardel; M Bakkus; J Rapion; B De Moerloose; P Kastner; A Caye; J Vivent; V Costa; A Ferster; P Lutz; F Mazingue; F Millot; D Plantaz; G Plat; E Plouvier; M Poirée; N Sirvent; A Uyttebroeck; K Yakouben; S Girard; N Dastugue; S Suciu; Y Benoit; Y Bertrand; H Cavé
Journal:  Leukemia       Date:  2015-06-08       Impact factor: 11.528

Review 8.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.

Authors:  Anthony V Moorman
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941

9.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

10.  IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.

Authors:  Arian van der Veer; Marketa Zaliova; Federica Mottadelli; Paola De Lorenzo; Gertruuy Te Kronnie; Christine J Harrison; Hélène Cavé; Jan Trka; Vaskar Saha; Martin Schrappe; Rob Pieters; Andrea Biondi; Maria Grazia Valsecchi; Martin Stanulla; Monique L den Boer; Giovanni Cazzaniga
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
  10 in total
  5 in total

Review 1.  IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Authors:  Martin Stanulla; Hélène Cavé; Anthony V Moorman
Journal:  Blood       Date:  2020-01-23       Impact factor: 22.113

2.  Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.

Authors:  Jason H Rogers; Rohit Gupta; Jaime M Reyes; Michael C Gundry; Geraldo Medrano; Anna Guzman; Rogelio Aguilar; Shannon E Conneely; Tidie Song; Cade Johnson; Sean Barnes; Carlo D D Cristobal; Kristen Kurtz; Lorenzo Brunetti; Margaret A Goodell; Rachel E Rau
Journal:  Blood Adv       Date:  2021-10-12

3.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.

Authors:  Chunhua Song; Zheng Ge; Yali Ding; Bi-Hua Tan; Dhimant Desai; Krishne Gowda; Shantu Amin; Raghavendra Gowda; Gavin P Robertson; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Zafer Gurel; Soumya Iyer; Pavan Kumar Dhanyamraju; Meixian Xiang; Yuka Imamura Kawasawa; Nathalia M Cury; José Andrés Yunes; Mary McGrath; Joe Schramm; Ruijun Su; Yiping Yang; Zhijun Zhao; Xiaoguang Lyu; Markus Muschen; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

Review 4.  Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; Mignon L Loh; Stephen P Hunger
Journal:  Blood       Date:  2017-10-02       Impact factor: 22.113

5.  Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations

Authors:  Željko Antić; Jiangyan Yu; Simon V Van Reijmersdal; Anke Van Dijk; Linde Dekker; Wouter H Segerink; Edwin Sonneveld; Marta Fiocco; Rob Pieters; Peter M Hoogerbrugge; Frank N Van Leeuwen; Ad Geurts Van Kessel; Esme Waanders; Roland P Kuiper
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.